# Biological Therapy, Sargramostim, and Isotretinoin in Treating Patients With Relapsed or Refractory Neuroblastoma

> **NCT01334515** · PHASE2 · COMPLETED · sponsor: **Children's Oncology Group** · enrollment: 52 (actual)

## Conditions studied

- Recurrent Neuroblastoma

## Interventions

- **BIOLOGICAL:** hu14.18-IL2 fusion protein
- **DRUG:** isotretinoin
- **BIOLOGICAL:** sargramostim
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT01334515
- **Lead sponsor:** Children's Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-09
- **Primary completion:** 2013-12-31
- **Final completion:** 2019-09-30
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2019-10-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01334515

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01334515, "Biological Therapy, Sargramostim, and Isotretinoin in Treating Patients With Relapsed or Refractory Neuroblastoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01334515. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*